Actinium Pharmaceuticals, Inc.

ATNM

Healthcare|Biotechnology|US

$1.43

+0.13 (+10.00%)

DCF Value

$1.48

Tangible Book / Share

$0.97

Graham Number

$2.80

Cash / Share

$1.16

Next Earnings Report

Nov 13, 2026

EPS est. -$0.25 · Revenue est. $1.2M

Financing Filings (last 12 months)

No shelf registrations or offering prospectuses filed.

Upcoming Data Readouts (2)

May 2029

Est. completion

P1P2Non Hodgkin Lymphoma

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

NCT06768905n=30

Mar 2030

Est. completion

P1Sickling Disorder Due to Hemoglobin S

131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

NCT07015684n=24

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Jun 2022

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

NCT02665065

Recent Press Releases

Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease

Nov 4, 2026 · PRNewsWire

Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML

Nov 4, 2026 · PRNewsWire

Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models

Nov 2, 2026 · PRNewsWire

Actinium Pharmaceuticals Announces Inducement Grant to New Employee

Oct 30, 2026 · PRNewsWire

Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026

Oct 23, 2026 · PRNewsWire

Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

Oct 20, 2026 · PRNewsWire

Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

Oct 20, 2026 · PRNewsWire

Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026

Oct 19, 2026 · PRNewsWire

Actinium Pharmaceuticals Announces Inducement Grants to New Employees

Oct 16, 2026 · PRNewsWire

Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

Oct 16, 2026 · PRNewsWire

SEC Filings (25)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Oct 15, 2026	ARS	Annual report to holders	Document Index
Oct 15, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Oct 15, 2026	8-K	Material event	Document Index
Oct 9, 2026	S-8	Employee stock plan	Document Index
Aug 14, 2026	8-K	Material event	Document Index
Aug 7, 2026	10-Q	Quarterly report	Document Index
Jun 18, 2026	8-K	Material event	Document Index
May 29, 2026	8-K	Material event	Document Index
May 8, 2026	10-Q	Quarterly report	Document Index
Mar 30, 2026	10-K	Annual report	Document Index
Mar 26, 2026	8-K/A	Material event	Document Index
Feb 13, 2026	8-K	Material event	Document Index
Nov 26, 2025	8-K	Material event	Document Index
Nov 14, 2025	10-Q	Quarterly report	Document Index
Nov 5, 2025	ARS	Annual report to holders	Document Index
Nov 5, 2025	DEF 14A	Proxy / shareholder vote	Document Index
Aug 8, 2025	10-Q	Quarterly report	Document Index
Jul 29, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Jul 16, 2025	SC 13G/A	Passive 5%+ stake	Document Index
May 9, 2025	10-Q	Quarterly report	Document Index
May 9, 2025	8-K	Material event	Document Index
Mar 31, 2025	10-K	Annual report	Document Index
Nov 27, 2024	8-K	Material event	Document Index
Nov 14, 2024	10-Q	Quarterly report	Document Index
Nov 12, 2024	SC 13G/A	Passive 5%+ stake	Document Index